Executive brings more than 25 years of experience in life sciences

SAN JOSE, Calif. – Molecular Devices, LLC., a leading high-performance life science solutions provider and an operating company in the life sciences segment of Danaher Corporation (NYSE:DHR), today announced Mary Duseau’s appointment as its new president, succeeding interim president, Greg Milosevich.

“Mary brings more than 25 years of life science experience and a track record of achieving exceptional business results to Molecular Devices,” said Greg Milosevich, Vice President, and Group Executive Life Sciences Innovations Group at Danaher Corporation. “This is a testament to the way Mary leads by empowering teams to perform their best, prioritizing communication and collaboration in decision-making, and creating sustained value to ensure customer satisfaction and loyalty.”

Prior to joining Molecular Devices, Mary spent six years at Leica Biosystems, also a Danaher operating company. During her tenure, she served as Senior Vice President, Global Commercial Operations, where she was responsible for sales, service, customer experience, and people management for the nearly $1 billion business. Before Leica Biosystems, Mary was CEO and President for Roka Bioscience; Senior Vice President, Sales, for Andor Technologies; and Global Vice President, Sales and Marketing, as well as Business Unit Leader, Imaging and Detection, for PerkinElmer – now Revvity.

“In this short time as president, it’s clear that Molecular Devices’ innovative technology and diverse team are enabling a revolution of human health – and that’s really inspiring,” said Mary Duseau, President of Molecular Devices. “Having held such respect for this company throughout my career in the life sciences, I’m deeply energized by this opportunity to now work from within. It’s a critical time for us to continue leading as the industry shifts toward 3D biology, and as we help transform the way researchers approach therapeutic discovery and development to ultimately bring life-saving treatments to bedsides sooner, cheaper, and safer.”

Mary holds a BS in Biochemistry, from the University of Massachusetts. She’s based in San Jose, Calif., where Molecular Devices is headquartered.

About Molecular Devices, LLC.

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.

Molecular Devices is proud to be a part of Danaher, a global science and technology innovator. Together, we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. For more information, please visit www.danaher.com.